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Abstract

ROLE OF THE PEDIATRIC DENTAL PROVIDER IN HUMAN PAPILLOMAVIRUS (HPV)
EDUCATION
By: Meredith L. Dugoni, DMD
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Dentistry at Virginia Commonwealth University.
Virginia Commonwealth University, 2017
Thesis Advisor: Tegwyn Brickhouse, DDS, PhD
Director, Oral Health Services Research Core, VCU Philips Institute for Oral Health Research
Chair and Associate Professor, Department of Pediatric Dentistry

Purpose: This study investigates knowledge about HPV and examines if pediatric dental
providers should include HPV education for guardians of patients 10-18 years.
Methods: Legal guardians of 10-18 year-old patients of the Virginia Commonwealth University
Pediatric Dental Clinic were enrolled in this prospective cohort study. Participants completed a
baseline survey, were provided HPV education, completed an initial follow-up survey, and then
completed a 6-month follow-up survey.
Results: A total of 54 participants completed the baseline and initial follow-up surveys and 17
completed the 6-month follow-up survey. The average number of correct responses was 3.4 of 6

vii
knowledge questions, which significantly improved to 5.4 at follow-up (P<.0001). The greatest
increase in the percent responding correctly was regarding HPV and oropharyngeal cancer from
22% baseline to 91% at initial follow-up (P<.0001). Regarding Stage of Change, 14 (23%) of
those not initially in the Action group had improved at least 1 stage. At the 6-month follow-up, 3
(43%) guardians reported completing the HPV vaccine series.
Conclusions: These results demonstrate limited knowledge about HPV and highlight the
pediatric dental provider’s ability to educate. Since the greatest knowledge gap pertained to HPV
and oropharyngeal cancer, it is important for pediatric dental providers to increase their role in
HPV education. As oral cancers are the purview of dentists, practitioners should be involved
with their patients’ consideration of the HPV vaccine.

Introduction

Human papillomavirus (HPV) is mostly known in the United States due to its serious and
potentially life-threatening associations such as cervical cancers and genital warts; however,
many Americans do not understand much about the virus.1 Even less is known by the general
public about other consequences of the virus outside of the cervical region, particularly cancers
of the oropharynx.2 HPV is associated with cancers of the oropharynx region which is described
as the area including the palatine and lingual tonsils, posterior one-third of the tongue, soft
palate, and posterior pharyngeal wall.3,4 According to a recent Centers for Disease Control and
Prevention (CDC) report, HPV related cancers of the oropharynx and cervix are increasing,
whereas cancers of the oral cavity are decreasing.4,5 HPV vaccines that protect against the strains
that cause cervical cancer are available, and it is likely that the same HPV vaccines are effective
in preventing HPV infections in the oropharynx due to the same strains causing most cervical
and oropharyngeal cancers.4 Because HPV-related cellular changes are found in the
oropharyngeal region, it is important that dentists are able to identify possible HPV-related
infections and are able to communicate about HPV with their patients.4
HPV is the most common sexually transmitted infection in the US and it is associated
with approximately 4% of all human cancers.6,7 HPV infections are very common in Americans
with approximately 79 million people currently infected with HPV and approximately 14 million
new infections yearly.8,9 Most sexually active Americans will develop at least one HPV infection
in their lifetime, many of which are cleared by the human body naturally within two years.8,4
Activities that increase the risk of transmission of HPV include open-mouth kissing and oral
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sex.4,10 If the infection persists, the risk of other significant problems such as genital warts or
cancers increase.8,4 Individuals with compromised immune systems are also more likely have
HPV infections that their immune system is unable to clear.8
There are over 100 types of HPV. 4 Some strains are associated with cancers, genital
warts, or other cellular changes.4 Infection with certain HPV strains may lead to anogenital
cancers including anal, vaginal, vulvar, penile, cervical, and oropharyngeal cancers.6 HPV
accounts for approximately 99% of all cervical cancers and 66-70% of oropharyngeal cancers
that affect both men and women.6,11–13 Specifically, HPV-16 and HPV-18 account for 90-95% of
all HPV-related head and neck cancers and 80-90% of HPV-related cervical cancers.4,5,14 In the
oropharynx, HPV has a preference for lymphoepithelial tissue of the Waldeyer ring and is most
commonly spread through deep kissing or oral sex, but may also be spread by vertical
transmission.4,15–17
While HPV-related cancers are more common in women, approximately 36% of HPVrelated cancers occur among men.13 In general, oropharyngeal cancers are about four times as
common in men than in women.13 Recent data shows that in the United States more than 31,000
new cases of HPV-associated oropharyngeal cancers are diagnosed in women and 12,638 are
diagnosed in men each year.18
There are multiple ways to avoid HPV and HPV-associated health problems. These
include safe sex practices such as condom use during sexual activity, mutually monogamous
relationships, and abstinence.8,19 Vaccines are available to prevent multiple strains of HPV,
including high-risk types HPV-16 and HPV-18 which are more likely to cause cancer, and lowrisk types HPV-6 and HPV-11 that cause genital warts.9,19,20 Two types of HPV vaccines are
currently used in the United States, including quadrivalent and 9-valent types.9,21,22 The

2

quadrivalent and 9-valent types protect against HPV-6, HPV-11, HPV-16, and HPV-18.9 In
addition, the most recent 9-valent vaccine can prevent HPV types 31/33/45/52/58 which are
responsible for about 10% of HPV-associated cancers.9,12 Timing of the vaccination is crucial,
and it is important that the vaccine be given before any possible sexual exposure.23 It is
recommended that the HPV vaccines be given to both male and female children between the
ages of 11-12 and as early as 9, with catch-up doses available until age 26 for females and age 21
for males.24 In a recent 2016 update, the CDC recommends that healthy 9- to 15-year-olds who
receive the vaccine may receive two doses of the HPV vaccine at least 6-12 months apart and
other teens and young adults who start the series after 15 years of age must have three doses of
the HPV vaccine to be effective.25 However, males may receive the vaccine until age 26 if they
are immunocompromised or are having sex with men.24 It is important that every child be
immunized to enhance herd effects and limit disease burden.11,26
Multiple barriers to HPV vaccination have been identified, with provider
recommendation being the strongest predictor of adolescent HPV vaccination.6,27–29 Research
shows that only 15-64% of physicians report that they recommend the HPV vaccine to early
adolescents.30–32 Providers are also much less likely to recommend the vaccine to males and
guardians of male children.31 Lack of awareness and inadequate information and knowledge
about HPV has also been shown to be a significant barrier to vaccination.6,1,33,34 In a study
regarding the knowledge of adolescent girls regarding HPV, they found that 40.9% of adolescent
women who declined the vaccine stated the reason they declined was due to inadequate
information.1 Strides are being made to increase awareness of HPV and the HPV vaccine,
including a recent Merck 2016 campaign to publicize possible consequences of HPV in both men
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and women. According to research, other barriers include the cost of the vaccine, concerns
regarding sexual activity, safety concerns, and healthcare access.6,27,28,31,2,30
It is estimated that 39.9% of females and 5.9% of males received the HPV vaccine in
2013.35 Of those, only 2% of females and 9% of males reported receiving the first dose at age 1112 which is the ideal age of vaccination.35 It is very important to vaccinate children during the
appropriate age range because HPV vaccines are preventive and not therapeutic.23,36 In order to
increase vaccination rates in the United States parents and adolescents need to learn about HPV,
and providers need to regularly recommend the vaccine.6 A limited number of providers are
recommending the vaccine. As a result, parents who otherwise might choose to vaccinate their
children are not even given the option. Low vaccination rates are a public health concern due to
the highly infectious nature of HPV.35,37
The purpose of this study has three aims: First, to determine the effects of education and
provider recommendation in the pediatric dental setting on knowledge and understanding of
HPV; second, to determine the guardian’s readiness for change regarding HPV vaccination for
their children before and after education in the pediatric dental setting; and third, to determine
HPV vaccine follow-up in those patients who were not yet vaccinated and whose guardian
received educational information.
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Materials and Methods

This prospective cohort study was approved by the Institutional Review Board, Committee on
Human Research of Virginia Commonwealth University (VCU), Richmond, Virginia. Those
consenting to participate in the study were recruited from the VCU Pediatric Dental Clinic
between May 2016 and September 2016. Participants were required to be a legal guardian of one
or more of the clinic’s patients 10-18 years of age who presented for a new patient
comprehensive or six-month periodic exam. Exclusion criteria included non-English speaking
guardians, guardians who chose not to participate in the study, and guardians who completed less
than 50% of the initial survey questions.
After the aims and procedures of the study were explained to the eligible participant,
informed consent was obtained. The guardian then completed an 18-item questionnaire regarding
demographic information, attitude, awareness, and knowledge of HPV. Questions to determine
the participants Stage of Change were also incorporated in the questionnaire. The Stage of
Change questions were modeled after an instrument developed at the University of Rhode Island,
provided by Dr. Andrea Paiva (Table 1). Educational materials provided by the CDC and the
investigators were given to the participant to read. Clarifying questions were answered but no
other discussion took place at this time. Following the educational information, an 8-item survey
was given to the participant with questions that were repeated from the first survey including the
Stage of Change question. Participants were then able to ask questions and comment on their
own experiences if they so desired. All activities including obtaining consent, taking surveys,
and education took place in the participant’s child’s operatory room during the child’s dental
appointment. Approximately six months following the initial survey date participants were
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contacted via email or phone for a final survey. For those who provided an email address, a
survey was emailed to them. Participants who provided a phone number were called directly and
asked the survey questions verbally. Six-month follow-up surveys were sent the first Monday of
the month closest to the 6-month follow-up date. Participants that enrolled at the end of May and
during the month of June were sent the follow-up survey the first Monday of December,
participants that enrolled in July were sent the follow-up survey the first Monday of January, and
those who enrolled in August and the beginning of September were sent the follow-up survey the
first Monday of October. Study data were collected and managed using Research Electronic Data
Capture (REDCap) electronic data capture tools system.38 REDCap is a secure, web-based
application designed to support data capture for research studies.
Approval for this study was obtained from the Institutional Review Board, Committee on
Human Research (VCU IRB# HM 20006593).
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Table 1: Stages of Change
Have any of your children initiated the HPV vaccine
series (had at least 1 shot in the series)?

Stage of Change

Yes, and they have completed the series

Action/Maintenance

Yes, and they will complete the series

Preparation

Yes, but they will not complete the series

Precontemplation

No, but they will be starting the series in the next 30
days

Preparation

No, but they will be starting the series in the next 6
months

Contemplation

No, and I have not thought about them starting the HPV
vaccine series

Precontemplation

No, and I do not what then to be vaccinated for HPV

Precontemplation

Statistical Methods
Sample demographics were summarized using descriptive statistics. Changes in correct
responses for various knowledge questions were compared using McNemar’s Chi-squared test.
Changes in overall number of questions correct was tested using paired t-test. Changes in Stage
of Change were assessed using McNemar’s Chi-squared. All analyses were performed in SAS
EG v. 6.1 with a 0.05 significance level.
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Results

A total of 56 individuals enrolled in the study, of which 54 completed the baseline and initial
follow-up surveys, and 17 completed the 6-month follow-up survey. Participants were
predominantly female (92%) with 1-2 children aged 10-18 (78%). Full demographics are given
in Table 2.
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Table 2: Sample Demographics

Gender

Total
Sample
(n=54)

n, %
6 Month Followup (n=17)

P-value*
0.2929

Male 4, 8%
0, 0%
Female 49, 92%
17, 100%
Number of Children 10-18
0.6985
1 28, 53%
8, 47%
2 13, 25%
6, 35%
3 8, 15%
2, 12%
4+ 4, 8%
1, 6%
Children 19+
0.3995
0 34, 65%
9, 53%
1 12, 23%
6, 35%
2 2, 4%
1, 6%
3 2, 4%
1, 6%
4+ 2, 4%
0, 0%
Race/Ethnicity**
Black or African American 35, 65%
11, 65%
1
Hispanic/Latino 4, 7%
1, 6%
1
White 16, 30%
6, 36%
0.5402
American Indian/Alaska
Native 1, 2%
0, 0%
1
Asian 1, 2%
0, 0%
1
Parent's Education Level
0.1159
Some High School 7, 13%
2, 12%
High School 17, 33%
2, 12%
Associates Degree 6, 12%
2, 12%
Some College 15, 29%
8, 47%
College Graduate 4, 8%
1, 6%
Master's Degree 3, 6%
2, 12%
Parent's Age
0.5109
20-30 6, 11%
2, 12%
31-40 24, 44%
7, 41%
41-50 16, 30%
7, 41%
50+ 8, 15%
1, 6%
*P-value from Fisher's Exact Test of Demographics between those who
completed 6-month follow-up and those who did not
**Participant was able to select multiple answer choices
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Knowledge Questions
At baseline, the average number of correct responses for each respondent was 3.4 out of 6
questions. There was a significant improvement at follow-up with an average number of correct
responses increasing to 5.4 (p-value<0.0001). Looking at the individual questions, the greatest
increase in the percent responding correctly was seen in “Does Human Papillomavirus cause
mouth or throat (oropharyngeal) cancer?” At baseline, only 22% of respondents correctly
selected “Yes” and at follow-up this increased to 91% (p-value<0.0001). Complete breakdown of
questions is given in Table 3.

Table 3: Results from Knowledge Questions at Baseline and Initial Follow-up

Individual Questions
Do you think it is important for female adolescents
between the ages of 11-26 to receive the HPV vaccine?
Do you think it is important for male adolescents between
the ages of 11-26 to receive the HPV vaccine?
Does Human Papillomavirus cause cervical cancer?
Does Human Papillomavirus cause mouth or throat
(oropharyngeal) cancer?
Can people spread Human Papillomavirus without
knowing it?
Is getting Human Papillomavirus preventable by getting
the HPV vaccine?
*McNemar's Chi-Squared

n, % Correct
Initial
FollowBaseline
up

P-value*

45, 83%

51, 94%

0.0339

45, 83%
30, 56%

52, 96%
49, 91%

0.0082
<0.0001

12, 22%

49, 91%

<0.0001

25, 46%

47, 87%

<0.0001

28, 52%

46, 85%

<0.0001

Stage of Change
At baseline, 21 of the 54 participants reported their child had already completed or started the
HPV series. Among the remaining participants, 7 were in Preparation, 7 were in Contemplation,
and 17 were in Precontemplation (2 did not respond). At the initial follow-up, there were not any
changes among those in Preparation or Contemplation. Seven of the 17 in Precontemplation had
10

improved to either Preparation (n=2, 11%) or Contemplation (n=5, 29%). None of the
respondents regressed in their Stage of Change. Full results are given in Table 4.

Table 4: Stages of Change at Baseline and Follow-up
Baseline
Action
Preparation
Contemplation
Precontemplation
Total

Follow-Up #1
Action Preparation Contemplation
21
0
0
0
7
0
0
0
7
0
2
5
21
9
12

Precontemplation
0
0
0
10
10

Overall, 89% of respondents responded that they were more likely to vaccinate their children
against HPV after learning more about it from their pediatric dental provider (Table 5).

Table 5: Attitudes Towards Vaccinating Against HPV after Intervention
Which of the following best describes your attitude
towards the HPV vaccine?
I am more likely to vaccinate my child(ren) against
HPV since learning more about it
There is the same likelihood I will vaccinate my
child(ren) against HPV
I am less likely to vaccinate my child(ren) against HPV
since learning more about it.
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n, %
47, 89%
5, 9%
1, 2%

Total
21
7
7
17
52

Six Month Follow-up
A total of 17 participants completed the 6-month follow-up questionnaire, for a 6-month followup rate of 31%. Demographic variables were compared with those who did not respond to
determine if there was respondent bias. There were no differences in gender, age, race/ethnicity,
education level, or number of children (Table 2).

Knowledge Questions
Responses to knowledge questions maintained an improvement over baseline but a decrease
from the post-education knowledge (Figure 1). The greatest decrease in knowledge was seen for
the question regarding HPV and oropharyngeal cancer (94% to 53%). The decrease in
knowledge from post-education to 6-month follow-up was not statistically significant for the
questions regarding: importance of males (p-value=0.4795) or females (p-value=0.4795)
receiving HPV vaccine, HPV causing cervical cancer (p-value=0.3173), or HPV vaccine being
preventative (p-value=0.1025).
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Table 6: Knowledge Over Time for Individuals with 6-month Follow-up
n, %

Individual Questions
Do you think it is important for
female adolescents between
the ages of 11-26 to receive
the HPV vaccine?
Do you think it is important for
male adolescents between the
ages of 11-26 to receive the
HPV vaccine?
Does Human Papillomavirus
cause cervical cancer?
Does Human Papillomavirus
cause mouth or throat
(oropharyngeal) cancer?
Can people spread HPV
without knowing it?
Is getting HPV preventable by
getting the HPV vaccine?
*McNemar's Chi-Squared
**Significant at alpha = 0.05

Initial
FollowBaseline up

P-values*
6
Month
Followup

Baseline:
Followup

Followup: 6
Month
Baseline: Follow6-Month up

15, 88%

17, 100% 15, 88%

0.4795

1

0.4795

14, 82%

17, 100% 15, 88%

0.2482

0.5637

0.4795

15, 88% 0.0253** 0.0455**

0.3173

11, 65%

16, 94%

5, 29%

16, 94%

10, 59%
10, 59%

9, 53% 0.0009** 0.0455** 0.0196**

16, 100% 12, 75% 0.0233**
16, 94%
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12, 71% 0.0143**

0.0833

0.1336

0.1573

0.1025

Figure 1: Correct Responses to Knowledge Questions Over Time (n=17)
a
100%

a
88%

100%
90%
80%

a
88%

70%

a
100%

a
82%

a
88%

60%

b
94% b
88%

a
65%

50%

a
29%

40%
30%
20%
10%

0%

b
94%

Does Human
Do you think it is Do you think it is
Papillomavirus
important for
important for
male adolescents cause cervical
female
cancer?
between the ages
adolescents
between the ages of 11-26 to receive
of 11-26 to receive the HPV vaccine?
the HPV vaccine?

Baseline

Follow-up

c
53%

b
100%
a
59%

a,b
75%

b
94%
a
59%

a,b
71%

Does Human Can people spread Is getting HPV
HPV without
preventable by
Papillomavirus
knowing it?
getting the HPV
cause mouth or
vaccine?
throat
(oropharyngeal)
cancer?

6 Month Follow-up

*Timepoints with different letters were significantly different from McNemar’s chi-squared tests

Readiness for Change
At the 6-month follow-up, 4 of the 17 respondents demonstrated an increase in their Stage of
Change for HPV vaccination (Table 6). Three participants had moved into Action, indicating
completion of the HPV vaccine for at least one child in the 6-month time period. At 6-month
follow-up no participants were staged as Precontemplation. Two remained in Contemplation and
one in Preparation. One respondent failed to respond to the question regarding their Stage of
Change.
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Table 7: Readiness for Change at 6-month Follow-up
Baseline
Action
Preparation
Contemplation
Precontemplation
Total

Action
9
1
1
1
12

6 Month Follow-up
Preparation Contemplation
0
0
1
0
1
2
0
0
2
2

15

Precontemplation
0
0
0
0
0

Total
9
2
4
1
16

Discussion

Human papillomavirus (HPV) is highly infectious and it is estimated that 14 million new
infections occur every year, affecting people of all races and genders.8 Although the virus infects
a high percentage of Americans, there are vaccines available that prevent the most malignant
strains of HPV. HPV affects males and females but the vaccine has historically been targeted at
females due to the prevention of up to 90% of HPV-related cervical cancers.11,39 We now
understand more about the virus and that it causes many types of cancers in both sexes including
cervical, vulvar, vaginal, penile, anal and oropharyngeal cancers. Oropharyngeal cancers are
approximately 4 times more common in males than in females, however less men are vaccinated
against HPV than females.18 It has been shown that HPV is associated with 12-70% of
oropharyngeal cancers.39,40 There are very low vaccination rates in Americans which is a concern
due to the highly infectious and potentially malignant nature of HPV.4,40–42 Families regularly
visit their pediatric dentist every six months from ages one year to 18 years, which gives
pediatric dentists a unique opportunity to impact both their dental and overall health. Due to
effects of HPV on the oropharynx, pediatric dentists may be an ideal healthcare provider to
educate and recommend the HPV vaccine to their patients in the age range of 10-18 years in
addition to their primary care medical provider.
The sample demographics can be seen in Table 2. The majority of participants were
female and Black or African American. This is expected due to the urban location of the VCU
Pediatric Dental Clinic in Richmond, VA. It has also been demonstrated that mothers are more
likely than fathers to accompany their children to dental appointments which is the case for this
sample.43 The majority of our participants had one child aged 10-18 years, but it was also
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common to have two children in that age rage, or one child that was over 19 and one that was
between 10-18 years old. This is important because it has been shown that many pediatricians do
not recommend the HPV vaccine until at earliest 10 years of age, but more commonly 13-15
years, if at all.2,30,44 According to the Advisory Committee on Immunization Practices (ACIP),
the recommended age of vaccination is 11-12 years but the vaccine may be given as soon as 9
years.25
Results of this study suggest that written educational information at the pediatric dental
office is a successful way to educate guardians about HPV. Participants answered 5.4 out of 6
questions correctly following written educational information about HPV which significantly
increased from a response of 3.4 correct answers prior to education (p-value<0.0001) (Table 3).
Following education, 89% of participants reported that they were more likely to vaccinate their
child against HPV (Table 5). These results demonstrate that education in a written format is
effective and that they are more likely to act after receiving educational information about HPV.
Findings by Dempsey et al. also show that written information is a successful way to educate
parents about HPV and research by Chan et al. and Davis et al. also demonstrate that when
guardians read information about HPV they become more supportive of the HPV vaccine.45–47
While this research supports previous findings, this is the first study to educate about HPV in the
pediatric dental office.
While at baseline, 83% of participants in this study understood that the HPV vaccine was
important to both males and females, national vaccination rates are nowhere near the national
goal of 80%.48 In 2012, 28.1% of females and 6.9% of males aged 13-15 had received at least
three doses on the HPV vaccine, with males having much lower vaccination rates than
females.31,47,48 This raises concerns about barriers that families face regarding HPV vaccination.
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Berenson et al. described many barriers that affect vaccination rates with the greatest barriers
being provider recommendation and inadequate information and knowledge.6 While some
guardians understand that HPV vaccination is important, it has been shown that physicians are
not recommending the vaccination regularly which plays a role in low vaccination rates.47
Berkowitz et al. found that only 14.5% of physicians recommend the vaccine to all ageappropriate females.2 Javanbakht et al. demonstrated that pediatric medical providers may
perceive parental misconceptions as a barrier to HPV recommendation, which could be
overcome with education.49
At baseline, 91% of participants had heard of HPV or the HPV vaccine but only 41% of
the participants were in the Action stage of change, and 13% were in the Preparation stage of
change. Immediately following education, five participants that were in Precontemplation
improved to Contemplation and two improved to Preparation (Table 4). It is important to note
that no participants regressed in their stage of change, showing that education only improved the
chance of participants getting the vaccine for their children. Because of a discrepancy of
participants who had heard about HPV and how many children had actually received the vaccine,
it is possible that participants had heard about the vaccine through television commercials,
advertisements, or word-of-mouth but it was not addressed at their children’s well-child visits.
This information further suggests that many of the participants had barriers to overcome before
getting the vaccine.
At baseline, only 52% thought that getting HPV was preventable by the vaccine and 56%
understood that HPV could cause cervical cancer (Table 3). Even less (22%), knew that HPV
could cause oropharyngeal cancer (Table 3). Research by Berkowitz et al. shows that physicians
are knowledgeable about the fact that HPV vaccine prevents cervical cancer but are much less
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likely to be knowledgeable of other HPV-associated cancers including those of the oropharynx.2
This is important because if physicians are not knowledgeable about all HPV-associated cancers,
they are not able to educate and recommend the vaccine appropriately. This demonstrates that
only 38% of pediatricians know that HPV is effective in preventing oropharyngeal cancer, and it
is even lower in OB/GYNs (34%) and internists (20%).2 Following education, correct answers to
“Does HPV cause cervical cancer?” and “Does HPV cause mouth or throat (oropharyngeal)
cancer?” increased to 91% for both questions (p-value <0.0001) (Table 3).
The results of this study show that the majority of participants were more likely think
positively about HPV and act in a positive way concerning the HPV vaccine after learning about
it at their pediatric dentist office. Previous research has not taken place in the pediatric dental
setting but it has surveyed the general public, adolescents, or parents and as well patients in a
medical setting. Involving the pediatric dentist in education combats the major barriers to HPV
vaccination including provider recommendation, lack of knowledge, and access to information.
Due to HPV’s predilection for the oropharynx and oral cavity, pediatric dentists have a
responsibility to their patients to make sure they are educated about HPV and prevention
strategies.
The American Academy of Pediatric Dentistry (AAPD) has a Child and Adolescent
Vaccination Schedule in the AAPD 2016-17 Definitions, Oral Health Policies, and Clinical
Practice Guidelines which has been approved by the Advisory Committee on Immunization
Practices (ACIP).50 The Childhood and Adolescent Immunization Schedule does not list the
pediatric dentist’s responsibilities as far as educating or upholding the vaccination schedule for
their patients. It is assumed that the pediatric dentist should be aware of the schedule but they do
not have any further specific obligations by the AAPD to uphold the schedule. Just being aware
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of the schedule and relying on the child’s pediatrician to enforce the HPV vaccine is not enough,
as demonstrated by the very low vaccination rates in the United States. This innovative research
suggests that pediatric dentists should consider including HPV education and an HPV vaccine
recommendation as part of their anticipatory guidance for parents of children age 9-18 in order to
increase vaccination rates and prevent HPV-associated cancers.
Patients are regularly seen every 6 months by their pediatric dental provider from age 1
through age 18 or 21. If a patient visits their pediatric dental provider every six months
beginning at age one, they will see their pediatric dentist at least 18 times before the patient turns
9 years old, which is the youngest age the HPV vaccine may be given. If the patient has dental
caries that need to be addressed the number of appointments is increased. This gives providers a
significant amount of patient contact time to build rapport before they begin discussing HPV and
the HPV vaccine with parents of their patients. Due to the frequent visits and the strong
relationships that pediatric dental providers build with their patients, pediatric dentists should be
involved in the discussion of their overall health including HPV and the HPV vaccine.
The limitations of this study are important to note. The demographics of the study may
not be generalizable due to the location and primarily Black or African American and low
socioeconomic patient population of the VCU Pediatric Dental Clinic as well as the majority of
female participants. This study was based on participant report through surveys which relies on
the participant being engaged in the education and taking time to fully complete the surveys
which could result in recall bias. There was a 100% response rate at the first follow-up, but it
decreased significantly at the 6-month follow-up where the participation rate was 33%.
Future research includes varying the way that educational information is presented such
as using verbal education and motivational interviewing. An outcome-based longitudinal
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prospective study would be valuable to determine the long-term effects of HPV education in the
pediatric dentist and the effects on actual vaccination rates.
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Conclusions

The purpose of this study was to investigate the public’s knowledge about HPV and examine if
pediatric dentists should include HPV education for guardians due to the increasing HPVassociated oropharyngeal cancer rates. Prior to education, only 22% of participants knew that
HPV could cause oropharyngeal cancer which significantly improved to 91% (p-value<0.0001)
following education. Eighty-nine percent of participants reported they were more likely to
vaccinate their child for HPV following the intervention. Following education, no participants
regressed in their stage of change, and 5 moved from Precontemplation to Contemplation and 2
moved from Precontemplation to Preparation. HPV education in the pediatric dental setting is
effective and it increases the likelihood that guardians will vaccinate their child for HPV. The
lack of knowledge, especially relating to oropharyngeal cancer, indicates the responsibility of
pediatric dental providers to educate guardians about HPV vaccination at every periodic and
comprehensive exam for patient age 10-18 years.
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Role of the Pediatric Dentist in Human Papillomavirus
(HPV) Education
Thank you for agreeing to be a participant in this study. Please complete the following questions.
Envelope Number:

__________________________________

What is your gender?
Male
Female
Other
If
you
selected
"Other" gender,
please
use
the
space
provided to
explain, if
desired.

__________________________________________

What is your age?
18-20 years old
20-30 years old
31-40 years old
41-50 years old
Greater than 50 years old
Please select your race/ethnicity (Select all that apply):
(Check all that apply)
American Indian or Alaska Native
Asian
Black or African American
Hispanic or Latino
Native Hawaiian or Other Pacific Islander
White
Other
Please select your level of education:
Some high school
High school graduate
Associates degree
Some college
College graduate (bachelor's degree)
Master's degree
Professional degree
Doctoral degree
How many children with age 10-18 do you have?
0 children
1 child
2 children
3 children
4 or more children
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How many children age 19 and older do you have?
0 children
1 child
2 children
3 children
4 or more children
Have you heard of the human papillomavirus (HPV) or the HPV vaccine?
Yes
No
Have any of your children completed the HPV vaccine series?
Yes
No
Have any of your children initiated the HPV vaccine series (had at least 1 shot in the series)?
Yes, and they have completed the series
Yes, and they will complete the series
Yes, but they will not complete the series
No, but they will be starting the series in the next 30 days
No, but they will be starting the series in the next 6 months
No, and I have not thought about them starting the HPV vaccine series
No, and I do not want them to be vaccinated for HPV
Do you think it is important for female adolescents between the ages of 11-26 to receive the HPV vaccine?
Yes
No
Unsure
Do you think it is important for male adolescents between the ages of 11-26 to receive the HPV vaccine?
Yes
No
Unsure
Has a doctor or other health professional ever recommended the HPV vaccine for your child/children?
Yes
No
Does Human Papillomavirus cause cervical cancer?
Yes
No
Unsure
Does Human Papillomavirus cause mouth or throat (oropharyngeal) cancer?
Yes
No
Unsure
Can people spread HPV without knowing it?
Yes
No
Unsure
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Is
getting
HPV
preventable
by
getting
the
HPV
vaccine?

Yes
No
Unsure
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Follow-Up HPV Survey
Please complete the following survey after you have read the educational material and
discussed HPV with your provider.
Have any of your children initiated the HPV vaccine series (had at least 1 shot in the series)?
Yes, and they have completed the series
Yes, and they will complete the series
Yes, but they will not complete the series
No, but they will be starting the series in the next 30 days
No, but they will be starting the series in the next 6 months
No, and I have not thought about them starting the HPV vaccine series
No, and I do not want them to be vaccinated for HPV
Do you think it is important for female adolescents between the ages of 11-26 to receive the HPV vaccine?
Yes
No
Unsure
Do you think it is important for male adolescents between the ages of 11-26 to receive the HPV vaccine?
Yes
No
Unsure
Has a doctor or other health professional ever recommended the HPV vaccine for your child/children?
Yes
No
Does Human Papillomavirus cause cervical cancer?
Yes
No
Unsure
Does Human Papillomavirus cause mouth or throat (oropharyngeal) cancer?
Yes
No
Unsure
Can people spread HPV without knowing it?
Yes
No
Unsure
Is getting HPV preventable by getting the HPV vaccine?
Yes
No
Unsure
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Which of the following best describes your attitude towards the HPV vaccine?
I am more likely to vaccinate my child(ren) against HPV since learning more about it
There is the same likelihood I will vaccinate my child(ren) against HPV
I am less likely to vaccinate my child(ren) against HPV since learning more about it.
Questions/Comments:
__________________________________________
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HPV Survey 6 Month Follow-up

The purpose of this research project is to investigate parents’ of adolescents attitudes and awareness regarding
human papillomavirus (HPV) and HPV vaccines. You are being asked to participate in this study because you are the
parent of a child between the ages of 10-18 and provided your email address for a 6-month follow-up. If you no
longer wish to participate, you can stop at any time.

If you decide to participate in this project, you will be asked to fill out a questionnaire about your attitudes and
awareness of HPV. The survey will last approximately 5 minutes. Participation is voluntary and you can withdraw at
any time. There are no costs for participating in this study other than the time you will spend filling out the survey
and the information you gain through the education. If you complete all 3 surveys you will be entered into a random
drawing to win 1 of 5 Kindle Fire tablets. If you win, you will be contacted via the email you provide on the initial
survey.

Data will be collected only for research purposes. Any and all data will be kept confidential, anonymous, and not
linked to any personal information. At the end of the project all data will be destroyed. Access to all data will be
limited to study personnel. If you have any questions or concerns about your participation in this project, contact:
Meredith Dugoni at dugoniml@vcu.edu or 804-828-9095
Your Name:

__________________________________

What is your gender?
Male
Female
Other
Since
you
selected
"Other"
gender, please
use
the
space
provided to
explain, if
desired.

__________________________________________

What is your age?
Less than 20 years old
20-30 years old
31-40 years old
41-50 years old
Greater than 50 years old
Please select your race/ethnicity (select all that apply):
(Check all that apply)
White
Hispanic or Latino
Black or African American
Native American or American Indian
Asian/Pacific Islander
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Please select your level of education:
Some high school
High school graduate
Associates degree
Some college
College graduate (bachelor's degree)
Master's degree
Professional degree
Doctoral degree
How many children with age 10-18 do you have?
0 children
1 child
2 children
3 children
4 or more children
How many children age 19 and older do you have?
0 children
1 child
2 children
3 children
4 or more children
Have you heard of the human papillomavirus (HPV) or the HPV vaccine?
Yes
No
Have any of your children completed the HPV vaccine series?
Yes
No
Have any of your children initiated the HPV vaccine series (had at least 1 shot in the series)?
Yes, and they have completed the series
Yes, and they will complete the series
Yes, but they will not complete the series
No, but they will be starting the series in the next 30 days
No, but they will be starting the series in the next 6 months
No, and I have not thought about them starting the HPV vaccine series
No, and I do not want them to be vaccinated for HPV
Have any of your children visited a pediatrician since the dental visit where you received educational materials on
HPV?
Yes
No
Unsure
If so, did the pediatrician or other medical provider recommend the HPV vaccine?
Yes
No
We have not visited the doctor since the last dental visit.
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Do you think it is important for female adolescents between the ages of 11-26 to receive the HPV vaccine?
Yes
No
Unsure
Do you think it is important for male adolescents between the ages of 11-26 to receive the HPV vaccine?
Yes
No
Unsure
Does Human Papillomavirus cause cervical cancer?
Yes
No
Unsure
Does Human Papillomavirus cause mouth or throat (oropharyngeal) cancer?
Yes
No
Unsure
Can people spread HPV without knowing it?
Yes
No
Unsure
Is
getting
HPV
preventable
by
getting
the
HPV
vaccine?

Yes
No
Unsure

Do
you
remember
reading
the
HPV
education
materials
that
were given
to you
by
the
pediatric
dental
office?

Yes
No
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